Today, the @AmerGeriatrics announced Veronica Rivera, MD, AGSF as the 2026 recipient of the AGS Clinician of the Year award. #AGS26 https://bit.ly/4sdbIHD 

Researchers will soon publish the first evidence-based guidelines for traumatic brain injury (TBI) recognition and management and return to duty in first responders – a group encompassing law enforcement officers, corrections personnel, firefighters and emergency medical technicians (EMTs). The authors will be the nearly 60 experts who convened at The Ohio State University in late March to pursue consensus on protocols surrounding six frameworks: workplace policies, injury prevention measures, challenges of recognizing injuries, diagnosis and treatment of the injury, mental health monitoring, and steps needed to get a concussed first responder back to work.

Medicaid insurance expansions between 2017 and 2023 sharply increased access to medication treatment for opioid use disorder in a period when fatal overdoses continued to climb, according to Rutgers Health researchers.

Their study, published in JAMA Network Open, finds that expanded Medicaid coverage saw meaningful population-level increases in the use of buprenorphine, a medication used to treat opioid use disorder.

Mayo Clinic researchers have developed a new method to identify which proteins are most likely to trigger an immune response — a discovery that could help improve transplant care, regenerative medicine and other areas where the immune system plays a critical role. The results, published in Biomaterials, challenge a common assumption in the field that all proteins are equally likely to provoke immune reactions.

About The Study: Among patients with commercial insurance, manufacturer-sponsored coupon use declined substantially between 2017 and 2024, whereas per-claim coupon amounts increased. These patterns may reflect several mechanisms. Manufacturers may be concentrating coupon programs on fewer products or for fewer patients while offering larger incentives in response to formulary pressures or expanded copay accumulator programs. Greater coupon amounts may also reflect higher underlying patient cost-sharing requirements.

About The Study: In this cohort study, a $35 monthly insulin out-of-pocket cap was found to be associated with significantly lower insulin out-of-pocket spending, increased access to insulin, and decreased blood glucose levels among Medicare beneficiaries with type 2 diabetes. These findings suggest federal cost-sharing policies could improve access and adherence to essential medications in diabetes and other chronic diseases.